{"id":"NCT00509795","sponsor":"Regeneron Pharmaceuticals","briefTitle":"Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)","officialTitle":"A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-Related Macular Degeneration","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-08","primaryCompletion":"2010-09","completion":"2011-07","firstPosted":"2007-08-01","resultsPosted":"2012-04-16","lastUpdate":"2012-12-28"},"enrollment":1217,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Macular Degeneration"],"interventions":[{"type":"BIOLOGICAL","name":"ranibizumab","otherNames":["Lucentis"]},{"type":"BIOLOGICAL","name":"aflibercept injection (VEGF Trap-Eye, BAY86-5321)","otherNames":["VEGF Trap-Eye","BAY86-5321"]},{"type":"BIOLOGICAL","name":"aflibercept injection (VEGF Trap-Eye, BAY86-5321)","otherNames":["VEGF Trap-Eye","BAY86-5321"]},{"type":"BIOLOGICAL","name":"aflibercept injection (VEGF Trap-Eye, BAY86-5321)","otherNames":["VEGF Trap-Eye","BAY86-5321"]}],"arms":[{"label":"ranibizumab 0.5mg Q4","type":"ACTIVE_COMPARATOR"},{"label":"aflibercept injection 2.0mg Q4","type":"EXPERIMENTAL"},{"label":"aflibercept injection 0.5mg Q4","type":"EXPERIMENTAL"},{"label":"aflibercept injection 2.0mg Q8","type":"EXPERIMENTAL"}],"summary":"This study is a phase 3, double-masked, randomized, study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration. Approximately 1200 patients will be randomized in the US and Canada.","primaryOutcome":{"measure":"Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF)","timeFrame":"Baseline and at week 52","effectByArm":[{"arm":"Ranibizumab 0.5mg Q4","deltaMin":94.4,"sd":0},{"arm":"IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4","deltaMin":95.1,"sd":0},{"arm":"IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4","deltaMin":95.9,"sd":0},{"arm":"IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8","deltaMin":95.1,"sd":0},{"arm":"Total","deltaMin":95.1,"sd":0}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG003","p":null}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":188,"countries":["United States","Canada"]},"refs":{"pmids":["32374423","31826853","25439429"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":94,"n":304},"commonTop":["NASOPHARYNGITIS","VITREOUS FLOATERS","Eye disorders PAIN","RETINAL HAEMORRHAGE","HYPERTENSION"]}}